EXPERIMENTAL MODEL AND APPROACHES TO INVESTIGATION OF THE ACQUIRED RESISTANCE TO TUMOR TRANSPLANTATION IN MICE

M. D. Lootsik, R. S. Stoika


DOI: http://dx.doi.org/10.30970/sbi.1501.647

Abstract


Introduction. An acquired resistance to experimental tumors was detected in animals that recovered from a primary transplanted tumor due to treatment or spontaneously, and demonstrated intolerance to a renewal tumor inoculation. This phenomenon is much less frequently observed, although it is of great scientific interest and medical significance. Here, we have addressed the expression of the resistance phenomenon in a model tumor in mice – Nemeth–Kelner lymphoma (NK/Ly).
The aim of our study was to elaborate a reproducible method for induction of resistance to transplantation of lymphoma NK/Ly in mice and to investigate the mechanisms of its development.
Methods and Results. Three schemes for induction of resistance were tested. The first one included treatment of tumor-bearing mice with vinblastine and, thereafter, reconvalescent animals were checked for the development of resistance expressed as a complete suppression of tumor growth after re-inoculation of tumor cells. Mice were inoculated intraperitoneally with NK/Ly ascitic cells and then subjected to 2–4 intraperitoneal injections of vinblastine at a dose of 1mg/g of body weight. The recovered mice were re-inoculated with tumor cells and the absence of tumor growth was considered as resistance development. The disadvantage of this approach is that less than 5% of mice achieve a long lasting recovery due to the treatment. The second scheme included the immunization of mice with intraperitoneal injection of the minimal number of viable tumor cells that do not cause tumor growth, but initiate the immune response. However, this approach was not effective, since there was no reliable number of cells correspon­ding to these demands. The minimal number of 15×103 injected cells per mouse caused a retarded but still progressive tumor growth. In the third scheme, the immunization of mice was conducted by the intraperitoneal injections of NK/Ly cells permeabilized with saponin. It should be noted that treatment with saponin leads to cell death with a minimal damage to cell morphology. The scheme of immunization with permeabilized NK/Ly cells appeared to be simple and effective. It provided a reproducible resistance to transplanted tumor and might be used as a model in studies of the mechanisms of this phenomenon. Cytological investigation of tumor and immunocompetent cells in ascites of control and of tumor-resistant mice was conducted. As revealed, the number of lymphocytes in ascites of tumor-resistant mice was about 4 times higher than such amount in the control (non-resistant) mice. A destruction of tumor cells by the adherent mono-nuclears was observed.
Conclusions. The method of induction of resistance to transplantation of experimental tumor NK/Ly by immunization of mice with tumor cells permeabilized with saponin is described. The intraperitoneal inoculation of tumor cells to the tumor-resistant mice caused the marked increase of the mononuclear leukocytes population in the peritoneal fluid, which showed a harmful effect upon tumor cells. Thus, the induction of resistance to transplantation of NK/Ly lymphoma in mice might be provided mainly via the mechanisms of cell immunity, in particular, by the appearance of cytotoxic lymphocytes specific to distinct tumor cells.


Keywords


lymphoma NK/Ly, mice, tumor transplantation, resistance

Full Text:

PDF

References


1. Berezhnaya N.M., Chekhun V.F. Immunology of tumor growth. Kiev: Naukova Dumka, 2005. 791 pp. (In Russian)

2. Boehm T. Design principles of adaptive immune systems. Nature Reviews Immunology, 2011; 11(5): 307-317.
CrossrefPubMedGoogle Scholar

3. Bulkina V.P. Vinblastine sulfate. In: Antitumor drugs. A Refepence Book. Kiev: Naukova Dumka, 1991. P. 44-48. (In Russian)

4. Crowther M.D., Dolton G., Legut M., Caillaud M. E., Lloyd A., Attaf M., Galloway S.A.E., Rius C., Farrell C.P., Szomolay B., Ager A., Parker A.L., Fuller A., Donia M., McCluskey J., Rossjohn J., Svane I.M., Phillips J.D., Sewell A.K. Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nature Immunology, 2020; 21(2): 178-185.
CrossrefPubMedPMCGoogle Scholar

5. Dyukalova M.B. Anticancer vaccines based on whole tumor cells or their derivates. Russian Biotherapeutic Journal, 2012; 11(4): 3-8. (In Russian)
Google Scholar

6. Gou Q., Dong C., Xu H., Khan B., Jin J., Liu Q., Shi J., Hou Y. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death & Disease, 2020; 11(11): 955.
CrossrefPubMedPMCGoogle Scholar

7. Kang M.J., Kim J.E., Park J.W., Choi H.J., Bae S.J., Kim K.S., Jung Y.-S., Cho J.-Y., Hwang D.Y., Song H.K. Comparison of responsiveness to cancer development and anti-cancer drug in three different C57BL/6N stocks. Laboratory Animal Research, 2019; 35: 17.
CrossrefPubMedPMCGoogle Scholar

8. Klein G., Sjogren H., Klein E., Helstrom K. Demonstration of resistance against methyl­cholantrene-induced sarcoma in primary autochtonous host. Cancer Research, 1960; 20; 1561-1572.
PubMedGoogle Scholar

9. Klein G., Sjogren H., Klein E. Demonstration of host resistance against sarcoma induced by implantation of cellophane films in isologous (singeneic) recipients. Cancer Research, 1963; 23: 84-92.
PubMedGoogle Scholar

10. Lebedeva E.S., Ataullakhanov R.I., Khaitov R.M. Vaccines for the treatment of malignant neoplasias. Immunologiya, 2019; 40(4): 64-76. (In Russian)
Google Scholar

11. Lilly R. Pathohistological technique and practical histochemistry. Moscow: Mir, 1969. 154-155. (In Russian)
Google Scholar

12. Lootsik M.D., Lutsyk M.M., Stoika R.S. Nemeth-Kellner lymphoma is a valid experimental model in testing chemical agents for anti-lymphoproliferative activity. Open Journal of Blood Diseases, 2013; 3(3A): 1-6.
CrossrefGoogle Scholar

13. Mosienko V.S., Shlyakhovenko V.O. The use of vaccines in treatment of oncological disease. Klinichna immunolohiia. Alerholohiia. Infektolohiia, 2006; 1(2): 18. (In Russian)

14. Nimmagadda S. Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. Cancers (Basel), 2020; 12(11): E3173.
CrossrefPubMedPMCGoogle Scholar

15. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., Sasayama Sh., Mizoguchi A., Hiai H., Minato N., Honjo T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science, 2001; 291(5502): 319-322.
CrossrefPubMedGoogle Scholar

16. Potebnya G.P., Lisovenko G.S., Chekhun V.F. Application of cancer vaccines of IEPOR series into clinical practice of oncological establishments of Ukraine. Nauka ta Innovacii, 2009; 5(1): 62-79. (In Ukrainian)
CrossrefGoogle Scholar

17. Sellei C., Ekhardt S., Nemeth L. Drugs in Treatment of Tumor Diseases. Akademiai Kiado: Budapest, 1975. 21-25. (In Russian)
Google Scholar

18. Sofyina Z.P., Syrkin A.B., Goldin A., Klein A. (Eds.). Experimental evaluation of antitumor substances in USSR and USA. Moscow: Medicina, 1980. P. 71-73, 76-77. (In Russian)
Google Scholar

19. Talmadge J.E., Meyers K.M., Prieur D.J., Starkey J.R. Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice23. JNCI: Journal of the National Cancer Institute, 1980; 65(5): 929-935.
CrossrefPubMedGoogle Scholar

20. Wei S. C., Duffy C. R., Allison J.P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery, 2018; 8(9): 1069-1086.
CrossrefPubMedGoogle Scholar


Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 M. D. Lootsik, R. S. Stoika

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.